Why Editas Medicine Stock Soared as Much as 42% Higher This Week [Yahoo! Finance]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: Yahoo! Finance
The catalyst that vaulted the gene editing specialist higher was the company's quarterly report, which included a surprise announcement. Alignment with the FDA On Wednesday, Editas Medicine released its fourth-quarter results, which were better than investors had hoped. The company generated revenue of $60 million and a loss per share of $0.23. Financial results generally take a back seat to other announcements with small drug developers, but these were notable, as analysts' consensus estimates were calling for revenue of $7.94 million and a loss per share of $0.54, so Editas sailed past expectations. Perhaps more importantly, Editas reported it had cash, cash equivalents, and marketable securities of $427.1 million as of Dec. 31, 2023. Management said it believes that this balance, along with the near-term licensing fees and up-front payments from Vertex Pharmaceuticals , will be sufficient to "fund operating expense and capital expenditures into 2026." Editas also announced
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewswire
- Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer [Yahoo! Finance]Yahoo! Finance
- Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
EDIT
Earnings
- 2/28/24 - Beat
EDIT
Sec Filings
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form DEF
- 4/10/24 - Form SC
- EDIT's page on the SEC website